For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
Search Posts
Op-Eds
Cannabis Legalization Clears One Hurdle, but Political Parties Must Compromise to Succeed
Last week, the House passed an historic bill to decriminalize cannabis at the federal level. Despite growing public and political support for such a…
City Journal
A Path to Better Days
It seems like a lifetime, but it was only one year ago that the world learned about a cluster of pneumonia cases linked to…
Blog
Documentary Exposes Global Nicotine Misinformation Campaign
What if, instead of a deadly “addictive” chemical, nicotine was a revolutionary therapy able to treat several debilitating conditions and, potentially, save billions of…
Wall Street Journal
Trump Isn’t the One Politicizing Science
Politics has infected many issues over the past four years and has now reached the supposedly objective halls of official medicine. In an editorial…
News Release
New CEI Paper Calls on EPA to Revise Faulty Assessment of Key Medical Supply Sterilant
A new report from the Competitive Enterprise Institute (CEI) finds faulty science by an EPA program led to an unfounded health scare around…
Study
EPA Should Revise Its Assessment of Medical Supply Sterilant
The COVID-19 crisis is a stark reminder of the importance of maintaining critical medical supplies. Not only must policy makers ensure that the market…